tiprankstipranks
Advertisement
Advertisement
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
PremiumThe FlyAtossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
1M ago
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting
Premium
Company Announcements
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting
1M ago
Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial
Premium
The Fly
Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial
2M ago
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
PremiumThe FlyAtossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
3M ago
Atossa Therapeutics announces addition of two biopharma executives to team
Premium
The Fly
Atossa Therapeutics announces addition of two biopharma executives to team
3M ago
VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
Premium
Market News
VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
4M ago
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
PremiumCompany AnnouncementsAtossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
4M ago
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
Premium
The Fly
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
4M ago
Atossa Therapeutics Issues 2026 Outlook and Strategic Update
Premium
Company Announcements
Atossa Therapeutics Issues 2026 Outlook and Strategic Update
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100